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Objectives: No data exist regarding "the best" hematocrit value after 
coronary artery bypass graft surgery. Transfusion practice varies, because 
neither an optimal hematocrit value nor a uniform transfusion trigger 
criterion has been determined. Methods: To investigate the optimal hemat- 
ocrit value, we studied 2202 patients undergoing coronary bypass. The 
hematocrit value on entry into the intensive care unit (IHCT) was catego- 
rized into three groups: high (>34%), medium (25% to 33%), and low 
(_<24%). Characteristics and adverse events (outcomes) were compared, 
and the effect of IHCT on the risk of myocardial infarction was determined 
by logistic regression. Results: High IHCT (_>34%) was associated with an 
increased rate of myocardial infarction (8.3% vs 5.5% vs 3.6%; p < 0.03, 
high, medium vs low) and with more severe left ventricular dysfunction 
(11.7% vs 7.4% and 5.7%; p = 0.006, high, medium vs low). Mortality rate 
increased with higher IHCT when all the high-risk subgroups were 
combined (8.6% vs 4.5% vs 3.2%; p < 0.001, high, medium vs low). By 
multivariate analysis, IHCT remained the most significant predictor of 
adverse outcomes (relative risk high vs low 2.22, 95% confidence interval: 
1.04 to 4.76). No characteristic, event, medication, or transfusion therapy 
confounded the relationship between IHCT and outcome. Conclusion: High 
IHCT is associated with a higher rate of myocardial infarction and is an 
independent predictor of infarction. On the basis of the risk of myocardial 
infarction, there is no rationale for transfusion to an arbitrary level after 
coronary artery bypass grafting. (J Thorac Cardiovasc Surg 1998;116:460-7) 
N o data exist regarding the "best" hematocrit (HCT) value after cardiopulmonary b pass. Cli- 
nicians have assumed that nemia increases the risk 
of myocardial ischemia after coronary artery bypass 
graft (CABG) operations. Several recent studies 
have suggested that there might not be an associa- 
tion between anemia and morbidity after CABG. 1' 2 
Therefore no safe lower limit of HCT has been 
established, yet the risks of transfusion are well 
delineated. 3 A wide variability exists in blood use for 
CABG operations. 4' s The difference in transfusion 
practice is probably a reflection of the lack of 
adequate data regarding morbidity and mortality 
risks for HCT levels after CABG. Any new data 
regarding relative outcome risks and HCT may have 
an impact on ational blood use and costs (15% to 
20% of blood is used in cardiopuhnonary b pass). 68 
In the patient undergoing CABG, the highest risk 
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Table I. Distribution of  preoperative and intraoperative characteristics of patients in the three IHCT groups 
HCT <-- 24% HCT 25%-33% HCT >- 34% 
(n = 248) (n = 1544) (n 410) 
Characteristic % (n) % (n) % (n) p Value 
Age (yr; mean, SD) 64.3 + 10.2 64.8 ± 10.1 63.7 ± 11.1 0.13 
BSA (me; mean, SD) 1.86 ± 0.20 1.93 ± 0.21 1.93 + 0.24 <0.001" 
Female gender 26 (65) 23 (356) 25 (104) 0.40 
History of smoking 62 (150) 67 (1,014) 70 (285) 0.06 
History of COPD t70 (42) 18.9 (293) 19.5 (80) 0.47 
History of anemia 10 (25) 7 (107) 5 (19) 0.03 
History of unstable angina 45 (109) 45 (695) 48 (193) 0.69 
History of MI 52 (127) 54 (820) 54 (218) 0.78 
History of CHF 32 (80) 32 (484) 30 (120) 0.71 
Prior CABS 9 (23) 12 (185) 16 (64) 0.04? 
History of thrombolysis$ 4 (11) 6 (92) 4 (15) 0.15 
History of aspirin use§ 67 (165) 64 (991) 59 (243) 0.11 
Emergency surgery 19 (47) 22 (333) 23 (96) 0.40 
Valve or other surgery 18 (44) 15 (235) 14 (58) 0.46 
Bypass time (rain; mean, SD) 113 _+ 49 113 ± 46 111 ± 48 0.63 
Crossclamp time (min; mean, SD) 65 + 32 66 + 32 64 _+ 30 0.72 
No. of grafts (mean, SD) 3.25 _+ 1.2 3.23 _+ 1.1 3.09 ± 1.1 0.05* 
History of diabetes 24.6 (61) 25.7 (397) 25.3 (103) 0.81 
History of renal disease 6.9 (17) 5.5 (85) 4.2 (17) 0.10 
Recent MI (-<31 days) 16.3 (40) 16.7 (254) 18.1 (73) 0.42 
History of peripheral vascular disease 20.6 (53) 23.4 (340) 22.6 (92) 0.93 
Canadian Heart Assoc classification IV 25.0 (55) 26.7 (350) 28.0 (97) 0.74 
Canadian Heart Assoc classification V 7.3 (16) 7.4 (97) 5.2 (18) 0.53 
Canadian Heart Assoc classification VI 5.0 (11) 5.5 (72) 4.9 (17) 0.93 
1HCT, Hematocrit value on entry into the intensive care unit; SD, standard deviation; BSA, body surface area; COPD, chronic obstructive pulmonm3' disease; 
M/, myocardial infarction; CHF, congestive h art failure; CABG, coronary artery bypass grafting. Calculated percents ake into account any missing data. 
*p -< 0.05 between low HCT and either medium or high HCT. 
]'p -< 0.05 between low HCT and high HCT group. 
SHistory of thrombolysis within 24 hours before CABG. 
§History of aspirin use within 7 days before CABG. 
per iod for adverse myocardia l  ischemic events is in 
the immediate  per ioperat ive period. 9' 10 Recent  data 
have shown that the per iod with in 1 to 2 hours after 
p ro tamine  admin is t ra t ion  is associated with the larg- 
est number  of e lectrocardiographic  changes of isch- 
emla. 1° The  HCT dur ing these first several hours  
after CABG represents  the sum total  of preopera-  
tive HCT,  hemodi lu t ion ,  b lood loss, f luid adminis -  
trat ion,  t ransfus ion therapy, and the t ransfus ion 
phi losophy ( t ransfus ion HCT trigger). A represen-  
tative HCT of that t ime interval  is the HCT on entry 
to the intensive care uni t  ( IHCT) .  In  a large-scale 
mul t i center  study, the re lat ionship between IHCT 
and adverse clinical outcomes was examined in an 
effort to answer  the quest ion:  Is there a "best" IHCT 
after CABG? 
Methods  
Patients. The Multicenter Study of Perioperative Isch- 
emia (McSPI) Cardiac Surgery Database was a prospec- 
tive observational study of 2417 patients in the United 
States undergoing elective CABG operations with or 
without other concurrent cardiac procedures. The study 
was designed to assess the frequency of adverse postop- 
erative outcomes and to determine the presence of pre- 
operative patient characteristics, a~ Between 100 and 108 
patients were enrolled at each of 24 centers from Septem- 
ber 1991 to September 1993 with the use of a standardized 
questionnaire that has been previously well described. 13 
The volume of intraoperative crystalloid and colloid was 
measured, as was the use of transfusion (red blood cells 
[RBCs], platelets, fresh frozen plasma, or cryoprecipitate) 
during and after the operation. Blood loss was assessed by 
chest tube drainage. 
Postbypass morbidity was defined as (1) low cardiac 
index (<1.5 L/min. m 2) or hypotension (arterial systolic 
pressure < 80 mm Hg for -> 10 minutes), or the admin- 
istration of three or more inotropic agents; (2) the pres- 
ence of myocardial ischemia by ST segment deviation or 
the use of intravenous nitroglycerin; (3) hypertension 
(systolic blood pressure > 180 mm Hg for -> 10 minutes), 
or tachycardia (heart rate > 100 beats/min for at least 10 
minutes). 
Adverse events. Adverse postoperative events included 
Q-wave myocardial infarction (MI), death, renal failure 
(necessitating hemodialysis), adverse central nervous ys- 
tem outcome (stroke, transient ischemic attack, or stupor/ 
coma at discharge), or severe left ventricular dysfunction 
necessitating the use of an intraaortic balloon pump. To 
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Fig. 1. Level (mean _+ standard deviation) of HCT on 
admission, on entry to the ICU, and at discharge according 
to IHCT group. Note that the three subgroups were similar 
at hospital entry and discharge. L, Low HCT (-<24%); 3//, 
medium HCT (25% to 33%); H, high HCT (->34%). 
determine the presence of a new Q-wave MI, one preop- 
erative and two postoperative 12-lead electrocardiograms 
(one collected on postoperative days 0 to 3 and one on 
days 4 to 10) were analyzed according to Minnesota Code 
criteria by three electrocardiographers at a central core 
facility (Ischemia Research and Education Foundation 
[IREF], San Francisco, Calif.), who were blinded to 
patients' identities and clinical courses. 12 
HCT. HCT values were recorded at hospital admission, 
on arrival in the intensive care unit (ICU), and at dis- 
charge. The minimum and maximum postoperative alues 
were also noted. The changes in HCT from admission to 
ICU entry and from ICU entry to discharge were calcu- 
lated for each patient. Previous studies either considered 
an HCT of 25% as a lower limit or were vague regarding 
a transfusion trigger. Experimental data suggest that HCT 
exceeding 33% may be associated with decreased tissue 
oxygen delivery, j3 We thus defined three groups of pa- 
tients on the basis of IHCT: low (-<24%), medium (25% 
to 33%), and high HCT (->34%). 
Association of IHCT and intraoperative and postoper- 
ative variables. To identify any differences among pa- 
tients with low, normal, and high IHCT values, we exam- 
ined preoperative and intraoperative characteristics in
each 1HCT group. Because IHCT was thought o be a 
consequence of many intraoperative factors, operative 
events including blood and fluid loss, postbypass morbid- 
ity, and the use of transfusion were carefully examined for 
the three IHCT groups. Rates of adverse postoperative 
outcomes were compared across IHCT groups. In addi- 
tion, these outcomes were examined in subgroups of 
patients at high risk for adverse events (patients with 
unstable angina, emergency CABG, reoperation, or a 
combination of these factors). ~)' ~4-17 All associations were 
examined by means of the X 2 test for categoric variables 
and either general inear modeling or the Kruskal-Wallis 
test for continuous variables.~S All tests were two-tailed. 
Multivariate analysis. We limited multivariate analyses 
to Q-wave MI, because this was the only outcome with a 
blinded diagnosis. First, we examined the effect of IHCT 
on risk of MI after adjustment for single variables. We 
also examined thc effect of site on the relationship be- 
tween IHCT and MI. Because no variable appeared to 
confound the relationship between IHCT and MI, we 
constructed a stepwise logistic regression model using 
variables previously reported in the literature (age, sex, 
history of MI, smoking, and reoperation CABG)] 4-17 The 
entry and stay c~ level were both set at 0.2 in this analysis 
(variable will remain ifp -< 0.2 and will be removed ifp > 
0.2). All IHCT levels were forced to remain in the model 
at all times. The Hosmer-Lemeshow test measuring ood- 
ness-of-fit was used to validate thc final stepwise logistic 
regression modeI. 19 
Results 
Patients. Interpretable lectrocardiographic and 
HCT values were available for a total of  2202 
patients. The demographic, preoperative, and intra- 
operative characteristics of the three IHCT groups 
are presented in Table I. Patients' ages ranged from 
28 to 95 years (mean .+ standard deviation: 64.6 _+ 
10.3 years), with 32% older than 70 years of age. 
CABG was performed on an emergency basis in 
nearly 25% of cases, and approximately 16% of 
patients underwent an additional cardiac procedure, 
primarily valve repair or replacement. 
HCT. Overall, mean HCT at hospital discharge 
was 25% lower than at admission (discharge HCT = 
30.8% _+ 4.2%, range = 20.1% to 51.8%; admission 
HCT = 39.8% _+ 4.8%, range = 28.0% to 54.4%). 
The IHCT had a mean of 29.7% _+ 4.7% and a range 
of 13.0% to 47.0%. "Medium" IHCT (25% to 33%) 
was found in 70% (n = 1544) of patients, "low" 
(-<24%) in 11% (n = 248), and "high" (>34%)  in 
19% (n = 410). Patients having a high IHCT were 
likely to have had higher HCT values at both 
hospital admission and discharge than patients with 
either low or medium HCT values (Fig. 1). IHCT  
decreased an average of 16 points from baseline 
hospital admission values in patients with low IHCT,  
versus 10 and 6 points in patients with medium and 
high IHCTs, respectively. 
Association between HCT and preoperative vari- 
ables. Demographic characteristics and medical 
history for the three IHCT groups are presented in 
Table I. Patients undergoing reoperation were more 
likely to have a high IHCT, and patients with a 
history of anemia, a low IHCT (Table I). Patients in 
the low IHCT group had a smaller body surface area 
and a lower mean weight (high IHCT:  81.2 + 17.8 
kg; medium IHCT: 80.7 + 15.6 kg; low IHCT:  
75.9 .+ 13.7 kg; p < 0.001, high vs low). Other 
preoperative clinical characteristics were similar 
among the three groups. 
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Table II. Volumes of fluid administered, percent of patients given an intraoperative and~or postoperative 
transfusion, and amount of chest ube drainage in the three IHCT groups' 
Day of 
Intraoperat~ve Intensive care unit operation 
Crystalloid or Packed RBCs FFP and Packed RBCs FFP and Chest tube 
colloid (ml) and whole blood Platelets cryoprecipitate and whole blood Platelets cryoprecipitate drainage (ml) 
(mean, SD; (mean, SD; 
IHCT median) % (n) % (n) % (n) % (n) % (n) % (n) median) 
HCT < 24% 3084 + 1476 50.0 (124) 23.0 (57) 20.2 (50) 66.9 (166) 23.0 (57) 22.6 (56) 774 ± 534 
(n = 248) (2715) (620) 
HCT 25%-33% 2995 + 1550 51.6 (797) 15.9 (246) 12.0 (185) 48.0 (741) 14.3 (221) 16.5 (255) 673 ± 556 
(n = t544) (2800) (542) 
HCT > 34% 2654 + 1699 49.5 (203) 14.4 (59) 10.5 (43) 32.2 (132) 13.4 (55) 16.6 (68) 638 ± 541 
(n = 410) (2500) (545) 
p Value 0,01 0.71 0.01 0.001 <0.001 0.001 0.06 0.008 
IHCT, Hematocrit value on entry into the intensive care unit; RBCs, red blood cells; FFP, fresh frozen plasma. 
Table III. Rates' qf adverse ischemic outcome in the whole study population sample and in high-risk subgroups 
stratified by IHCT group 
Whole study population Unstable angina Emergency CABG Redo CABG 
P P P P 
<24% 25%-33% >>-34% Value <24% 25%-33% >-34% Value ~24% 25%-33% >-34% Value <-24% 25%-33% >-34% Value 
No. 248 1544 
Q-wave MI; 3.6 5.5 
% (n) (9) (85) 
Severe LV 5.7 7.4 
dysfunc- (14) (114) 
tion; % 
(n) 
All cause 5.2 2.6 
mortality; (13) (40) 
% (n) 
410 109 695 193 47 333 96 23 185 64 
8.3 .03 5.5 6.6 10.4 .16 4.3 5.1 7.3 .66 4.4 6.5 14.1 .13 
(34) (6) (46) (20) (2) (17) (7) (1) (12) (9) 
11.7 .006 6.4 9.8 17.1 .004 12.8 15.6 18.8 .63 21.7 21.6 32.8 .19 
(48) (7) (68) (33) (6) (53) (18) (5) (40) (21) 
5.6 0.003 3.7 3.3 10.4 <.001 6.4 3.6 10.4 .03 13.0 5.9 14.1 
(23) (4) (23) (20) (3) (12) (10) (3) (11) (9) 
.09 
1HCT, Hematocrit value on entry into the intensive care unit; CABG, coronary artery bypass grafting; M1, myocardial infarction; LV,, left ventricular. 
Association between HCT and transfusion vari- 
ables. Differences in HCT level from admission to 
ICU entry were not explained by intraoperative 
RBC transfusion (Table II). The percentage of 
patients who received either platelets or fresh frozen 
plasma was higher in the tow IHCT group. Among 
those who did receive hemostatic products, the 
median number of units used was not different (8 
units of platelets per recipient for all IHCT groups, 
p = 0.55) (fresh frozen plasma low IHCT = 4 units; 
median IHCT = 2 units; high IHCT = 2 units, p - 
0.15). Intraoperative crystalloid and colloid admin- 
istration showed a statistically significant difference 
(Table II), with the low IHCT group receiving more, 
but the difference between the low and high IHCT 
groups of 430 ml is clinically insignificant. Mean 
chest tube drainage (Table II) was greatest in the 
low IHCT groups but, again, was not of clinical 
significance (136 ml difference between low IHCT 
and high IHCT). However, a higher proportion of 
patients with low IHCT had chest tube drainages 
exceeding 1500 ml on the day of the operation (high 
IHCT = 3.4%; median IHCT = 5.0%; low IHCT = 
8.5%,p = 0.O2). 
Intraoperative hypertension occurred more often 
in the low IHCT group, but no differences occurred 
in postoperative hemodynamics, catecholamine 
therapy, or vasodilators. 
Postoperatively, patients with low IHCT were 
most likely to receive RBC transfusion. Patients who 
received non-RBC transfusion in the operating 
room were more likely to receive a transfusion i the 
iCU. The proportion of patients returning to the 
operating room for hemorrhage did not differ be- 
tween groups (low: 3%; medium: 3%; high: l%;p - 
0.23). 
Association of IHCT with adverse outcome. Post- 
operative adverse vents differed between the IHCT 
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Table IV. Effect of IHCT group on risk of MI after adjustment for single variables 
IHCT < 24%; IHCT 25%-33%; IHCT > 34%; odds 
Adjusted valqable od& ratio odds ratio (95% CI) ratio (9,5% CI) 
None 1.00 1.55 (0.77-3.12) 2.40 (1.13-5.10) 
Prior histou of MI 1.00 1.52 (0.74-3.03) 2.40 (1.13-5.10) 
Recent MI 1.00 1.52 (0.75-3.06) 2.42 (1.14-5.13) 
Gender 1.00 1.56 (0.77-3.114) 2.41 (1.13-5.11) 
History of unstable angina 1.00 1.71 (0.82-3.58) 2.69 (1.23-5.93) 
History of angina 1.00 1.71 (0.82-3.57) 2.67 (1.21-5.87) 
History of CHF 1.00 1.53 (0.76-3.08) 2.45 (1.16-5.21) 
New York Heart Classification >3 1.00 1.55 (0.77-3.11) 2.40 (1.13-5.09) 
History of smoking 1.00 1.51 (0.75-3.05) 2.24 (1.05-4.76) 
Prior PTCA 1.00 1.54 (0.76-3.10) 2.38 (1.12-5.04) 
History of diabetes 1.00 1.55 (0.77-3.12) 2.41 (1.13-5.11) 
Age 1.00 1.53 (0.76-3.09) 2.44 (1.15-5.17) 
Age >70 yr 1.00 1.53 (0.76-3.09) 2.43 (1.15-5.17) 
Reopcration CABG 1.00 1.53 (0.76-3.08) 2.34 (1.10-4.97) 
->3 Vessels bypassed 1.00 1.55 (0.77-3.12) 2.40 (1.12-5.09) 
Left main disease 1.00 1.55 (0.77-3.12) 2.41 (1.13-5.11) 
Low ejection fraction (-<30%) 1.00 1.49 (0.70-3.15) 2.12 (0.93-4.80) 
CPB time 1.00 1.56 (0.77-3.13) 2.42 (1.14-5.13) 
CPB time ~>120 min 1.00 1.56 (0.77-3.14) 2,41 (1.14-5.12) 
IHCI; Hematocrit value on entry into the intensive care unit; MI, Q-wave myocardial infarction; CHF, congestive heart tailure; PTCA, percutaneous 
transluminal coronary angieplasty; CABG, coronary artery bypass grafting; CPB, cardiopulmonary b pass. Note: No difference in odds ratios testing different 
covariates as compared with the model using none. 
groups (Table III). Rates of Q-wave MI and severe 
left ventricular failure were lowest in patients with 
low IHCT and significantly higher in those with high 
IHCT (p = 0.03). Rates of postoperative central 
nervous ystem dysfunction and renal failure did not 
differ between groups: central nervous system dys- 
function: high IHCT = 4.4%, medium = 3.5%, 
low = 4.4% (p = 0.59); renal failure: high IHCT = 
6.6%, medium = 5.4%, low = 7.7% (p = 0.29). In 
the whole sample, mortality rates were similar in the 
low and high IHCT groups. However, high-risk 
patients tended toward increased all-cause mortality 
in the high IHCT group (high = 8.6%, medium = 
3.2%, low = 4.5%, p < 0.001). In patients with a 
history of unstable angina, high IHCT was associ- 
ated with a threefold increase in mortality. 
Fig. 2 demonstrates the rates of individual and 
combined ischemic adverse outcomes in patients 
stratified by 1HCT. In every category of adverse 
outcome other than death, patients with high IHCT 
had a greater risk. No other measures of HCT 
(admission, lowest and highest postoperative, or 
discharge values) were associated with any adverse 
outcomes. 
Confounding by intraoperative vents. To deter- 
mine whether high IHCT was a surrogate marker 
for intraoperative morbidity, and thus directly asso- 
ciated with outcome (e.g., patients who were in 
more clinically unstable condition after bypass may 
have been more likely to receive a transfusion and 
thus fall into the high IHCT group and, as well, have 
more adverse ischemic outcomes), we examined the 
association between IHCT, postbypass morbidity, 
adverse ischemic outcome, and the use of RBC 
transfusion therapy. As expected, patients who had 
a low cardiac index (<1.5 L/rain), hypotension, or 
who received three or more inotropic drugs during 
the immediate postbypass period were more likely 
to have an adverse outcome. However, the frequen- 
cies of these clinical variables were equally distrib- 
uted between the IHCT groups (Table I) and they 
were not independent predictors. 
Multivariate analyses. Institution did not con- 
found the relationship between level of IHCT and 
risk of MI. Logistic regression models of Q-wave MI 
risk in each IHCT group with covariates showed that 
none demonstrated different odds ratios (Table IV). 
Our final stepwise regression model (Table V) 
showed that IHCT was the most important predictor 
of Q-wave MI. Patients with high IHCT were more 
than twice as likely to have a Q-wave MI as patients 
with low IHCT (p = 0.04) and 1.4 times more likely 
than patients with a medium IHCT (p -- 0.31). In 
additional models including intraoperative ariables 
such as (1) RBC transfusion requirements (2) post- 
bypass igns of hemodynamic instability (e.g., hypo- 
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Table V. Final stepwise logistic' regression model 
odds ratios (OR) and 95% confidence intervals (CI) 
.[or prediction of postoperative Q-wave MI 
Variables in model OR (95% C1) p Value 
IHCT group 
-<24% 1 
24%-33% 1.44 (0.71-2.92) 0.31 
~>34% 2.22 (1.04-4.76) 0.04 
Age (yr) 
<60 1.00 
60-70 1.33 (0.83-2.14) 0.24 
>70 1.61 (0.98-2.64) 0.06 
Sex 
Male 1.00 
Female 1.38 (0.90-2.11) 0.14 
History of MI 
No 1.00 
Yes 1.88 (1.27-2.8) 0.002 
History of smoking 
No 1.00 




Yes 1.35 (0.83-2.21) 0.23 
OR, Odds ratio; CI, confidence intelwals; MI, myocardial infarction; 1HCT, 
hematocrit value on entry into the intensive care unit; CABG, coronary 
artery bypass grafting. 
tension, low cardiac index), and (3) site, the magni- 
tude and significance of these odds ratios for IHCT 
did not change. 
Discussion 
Patients and adverse events. Our results demon- 
strate that IHCT level after CABG is significantly 
related to adverse outcome. In multivariate analysis 
that examined a wide variety of possible predictors, 
IHCT was the most significant independent predic- 
tor of Q-wave MI. This finding suggests that anemia 
is well tolerated with respect o MI. 
Confounding variables. The finding that low 
IHCT was associated with fewer ischemic events was 
unexpected. Therefore it was of paramount impor- 
tance that confounding variables be examined. 
Transfusion and fluid administration were not 
greatly different between groups, and no indepen- 
dent relationship was detected between transfusion 
or fluid administration and MI. Although crystalloid 
fluid administration did statistically differ between 
low and high IHCT groups, the difference in volume 
(430 ml) was not clinically important. Although 
lower IHCT did appear to affect the use of hemo- 
static components and to be associated with in- 
creased bleeding, no relationship was identified 
20[ [-] L°w []Medium m High m 
~= 
Q Wave MI Severe Left All Cause Adverse 
Ventricular Mortality Ischemic 
Dysfunction Outcomes 
Fig. 2. Frequency of Q-wave MI, severe left ventricular 
dysfunction (intraaortic balloon pump use), all-cause mor- 
tality, and combined (all three) adverse ischemic outcome 
by the IHCT group. Low, HCT -<24%; Medium, HCT 
25% to 33%; High, HCT ~>34%. 
between the use of these blood components and M1 
rates. Decreasing the value of the cut point for low 
HCT below or above 24% did not alter our findings. 
If more severely ill patients (preoperatively or 
intraoperatively) were preferentially maintained at a 
higher IHCT (e.g., through transfusion, hemocon- 
centration, fluid restriction), then the association 
between high IHCT and adverse outcome could be 
easily explained. Therefore we examined whether 
patients with clinical signs of postbypass morbidity 
(low cardiac index, hypotension, hypertension, 
tachycardia, ischemia, or requirement for inotropic 
medications or intravenous nitroglycerin) were 
more likely to have higher IHCT levels. These 
seriously ill patients were equally distributed among 
the three IHCT groups. Thus perioperative morbid- 
ity was not a confounder. 
Limitations. Limitations of our study include the 
definition of outcome. New Q waves were chosen as 
a very strict and exclusive definition of MI. If other, 
perhaps more liberal definitions of MI (e.g., creatine 
kinase MB, troponin, myoglobin, or echocardio- 
graphic findings) had been used, the frequency of 
these events by IHCT group may well have been 
different. No association was found between IHCT 
and other ischemic adverse outcomes uch as stroke 
and renal failure. In addition, our study did not 
examine fibrinolytic state, platelet number, or func- 
tion, and HCT was examined at only five time 
points. More HCT values with extensive hemato- 
logic correlates could potentially provide more in- 
formation concerning cause and effect for the rela- 
tionship found. 
Prior work and potential causes. Prior research 
in animal models of anemia with both acute and 
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chronic coronary obstruction has been per- 
formed. 2°-22 Ischemia occurs across a wide range of 
HCT values from 17% to 42.5%. 2o-22 Previous case 
reports and single-center studies support our find- 
ings that anemia alone does not increase the risk of 
MI after CABG. 1 In two studies of eight and 224 
patients, HCT levels did not affect myocardial lac- 
tate flux, a measure of ischemia. 23' 24 In a small study 
of 14 patients, the oxygen content of the coronary 
sinus did not change with either hemodilution (to 
23%) or subsequent transfusion to 34%. 25 A case 
report of a patient with an HCT level of 5% 
described diffuse myocardial dysfunction, relieved 
with transfusion, but no postoperative MI. 2 In our 
study, even in patients with IHCT levels between 
13% and 18% (n = 13), no Q-wave MI or ventric- 
ular dysfunction occurred, nor were there any deaths. 
Perioperative MI and dysfunction are likely the 
result of multiple causes. 9 An increased IHCT level 
may precipitate ischemic injury via several mecha- 
nisms: (1) Increased blood viscosity may require 
additional work by the myocardium, as well as 
decreasing tissue oxygen delivery. 16 (2) Shear forces 
between the vessel walls and the blood increase as 
the concentration of red blood cells increases. In 
addition, platelets exposed to these greater shear 
forces are more likely to be activated, and increased 
lateral platelet migration exists. 26 Therefore the 
number of interactions per unit time between plate- 
lets and the endothelial walls increases. 27 These 
interactions between altered endothelium and acti- 
vated platclets may be important. 28 (3) With in- 
creased IHCT, the availability of nitric oxide, an 
inhibitor of platelet and neutrophil binding to endo- 
thelial cells, 29 may be decreased. (4) Liberated 
hemoglobin taken up by endothelial cells increases 
free radical production, 3°perhaps worsening endo- 
thelial dysfunction. 
In conclusion, on the basis of this study of 2202 
patients, low IHCT (<24%) at the conclusion of 
CABG operations appears to protect against Q- 
wave MI. Therefore our data do not support arbi- 
trary transfusion of RBC products to increase oxy- 
gen-carrying capacity after CABG. Furthermore, 
allowing a low IHCT to occur after CABG might 
decrease the morbidity and cost associated with 
transfusion and also preserve a scarce resource 
(allogeneic blood). Future randomized prospective 
trials will be required to discover the mechanisms 
involved, as well as to examine associations between 
IHCT and creatine kinase MB or ischemia by ST-T 
wave analysis. 
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